Product image of Metlinka 50 Mg/1000 Mg (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Metlinka 50 Mg/1000 Mg

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Metlinka 50 Mg/1000 Mg (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride and Sitagliptin, the active ingredients in Metlinka 50 Mg/1000 Mg, are a Biguanide and DPP‑4 inhibitor presented as a 1000 mg/50 mg oral tablet for use in adults with type 2 diabetes mellitus. The combination improves glycaemic control by reducing hepatic glucose output and enhancing insulin secretion in response to meals.

GNH India supplies Metlinka 50 Mg/1000 Mg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Tchaikapharma High Quality Medicines, Inc.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metlinka combines metformin and sitagliptin to address hyperglycaemia in the type 2 diabetes therapeutic pathway.

  • Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels to achieve target HbA1c.
  • Metabolic syndrome (as adjunct therapy): assists in attaining glycaemic goals when lifestyle measures are insufficient.
  • Adults requiring combination therapy: provides enhanced glucose control alongside diet and exercise.

How It Works

  • Metformin decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity, while sitagliptin inhibits the dipeptidyl peptidase‑4 enzyme, prolonging incretin activity and promoting glucose‑dependent insulin secretion. Together they address both insulin resistance and impaired insulin release, resulting in better overall glycaemic regulation.

Side Effects

Metlinka may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhoea: loose stools occurring early in therapy.
  • Abdominal discomfort: cramping or pain.
  • Headache: transient mild headache.
  • Metallic taste: altered taste perception.
  • Decreased appetite: reduced food intake.

Serious or Rare Side Effects

  • Lactic acidosis: rare but life‑threatening metabolic disturbance.
  • Severe hypoglycaemia: especially when combined with insulin or sulfonylureas.
  • Pancreatitis: acute inflammation of the pancreas.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Hepatic dysfunction: elevated liver enzymes or liver injury.
  • Renal impairment worsening: accumulation of metformin leading to toxicity.

Precautions & Warnings

Metlinka requires careful consideration of patient‑specific factors before initiation.

  • Renal function assessment: avoid or adjust dose in moderate to severe renal impairment.
  • Hepatic disease monitoring: use with caution in patients with liver dysfunction.
  • Alcohol consumption: limit intake to reduce risk of lactic acidosis.
  • Pregnancy and lactation: safety not established; weigh potential benefits against risks.
  • Drug‑induced hypoglycaemia: monitor glucose when used with insulin secretagogues.
  • Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Metlinka can interact with several medicines, influencing efficacy or safety.

Major Interactions (Avoid)

  • Iodinated contrast agents: may precipitate acute renal failure when combined with metformin.
  • Insulin or sulfonylureas: increase risk of severe hypoglycaemia.
  • Cimetidine: raises sitagliptin plasma concentrations.
  • Strong CYP3A4 inhibitors: may elevate sitagliptin levels.
  • Nephrotoxic drugs: exacerbate renal impairment, raising metformin exposure.

Moderate Interactions (Monitor Closely)

  • Diuretics: can affect renal clearance of metformin.
  • ACE inhibitors/ARBs: monitor renal function and potassium.
  • Warfarin: occasional alterations in INR may occur.
  • Beta‑blockers: may mask hypoglycaemia symptoms.
  • Oral corticosteroids: may increase blood glucose, requiring dose adjustments.

Frequently Asked Questions

Metlinka is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus. It combines metformin, which reduces liver glucose production, with sitagliptin, which enhances insulin secretion after meals, providing a complementary approach to glycaemic management.

Metformin Hydrochloride lowers blood sugar primarily by inhibiting hepatic gluconeogenesis and increasing peripheral insulin sensitivity. This reduces the amount of glucose released into the bloodstream and improves the uptake of glucose by muscle and fat tissues, helping to lower fasting and post‑prandial glucose levels.

The specific dose of Metlinka is determined by the prescribing healthcare professional based on individual patient factors such as renal function, glycaemic targets, and concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety of Metlinka in pregnancy and lactation has not been established. Healthcare providers must weigh potential benefits against possible risks before prescribing it to pregnant or nursing women, and alternative therapies may be considered when appropriate.

To order Metlinka, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metlinka combines a biguanide (metformin) with a DPP‑4 inhibitor (sitagliptin), offering dual mechanisms that many single‑agent therapies lack. Compared with sulfonylureas, it carries a lower risk of hypoglycaemia, and unlike GLP‑1 receptor agonists, it is administered orally rather than by injection.

Metlinka tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Keep the product away from moisture, heat, and direct sunlight to maintain stability and potency throughout its shelf life.

Metlinka is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a full glass of water. Patients must follow the dosing schedule prescribed by their healthcare professional.

The most serious risks include lactic acidosis, a rare but potentially fatal condition linked to metformin accumulation, and severe hypoglycaemia when used with other glucose‑lowering agents. Pancreatitis and severe allergic reactions are also rare but critical adverse events that require immediate medical attention.

Metlinka is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, and those with a history of lactic acidosis. Caution is also advised for individuals with significant hepatic disease or acute heart failure.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT